The relationship between measures of mood state and cognitive function was investigated in a sample of geriatric psychiatry inpatients. All were admitted to an urban hospital with varying degrees of cognitive impairment. Patients with diminishing negative affects and depressive symptoms during the course of hospitatization improved significantly on three cognitive tests, and half of the group members were no longer impaired according to their performance on a mental status exam. Correlations between cognition and mood-scale change scores were significant on tests emphasizing spatial processing and learning. Although the effects were modest in this heterogenous sample, the data demonstrate a significant influence of changing mood state on neuropsychological test performance.
C OGNITIVE impairment in patients with treatable psychiatric disease has been of interest since the late 19th century (Berrios, 1985) . Over the past half-century, the term "pseudodementia" has been applied to patients who initially present with cognitive impairment but demonstrate remarkable recovery with psychiatric intervention (Kiloh, 1961; Madden, Luhan, Kaplan, & Manfredi, 1952; Wells, 1979) . Many of the early reports were, however, anecdotal accounts or case studies, and the degree to which cognitive deficits actually improve during psychiatric treatment remains in question.
Beneficial effects of antidepressant therapy on cognitive function were first demonstrated by Sternberg and Jarvik (1976) . Memory tests were administered to major affective disorder patients before and after tricyclic antidepressant therapy. The patients were divided into subgroups based on changes in clinical ratings on the Zung Self-Rating of Depression Scale (Zung, 1965) . Those showing the greatest improvement in depressive symptoms and mood (i.e., responders) improved more on tests of immediate and long-term memory. More recently, Corwin and colleagues (Corwin, Peselow, Feenan, Rotrosen, & Fieve, 1990 ) studied memory changes in depressed outpatients at baseline and one month after tricyclic therapy. In this study, positive treatment response was defined as a 50% reduction on the Hamilton Depression (HDRS; Hamilton, 1960) and Montgomery-Asberg Depression Rating (MADRS; Montgomery & Asberg, 1979) Scales. Depressed patients showing minimal response to treatment (i.e., nonresponders) did not improve on a test of recognition memory, whereas responders improved significantly. Likewise, Abas, Shakian, and Levy (1990) found that depressed patients followed over a two-year period improved significantly on several memory tests. Thus, there is evidence that memory deficits found in affective disorder patients respond to treatment.
Only a few studies have examined cognitive changes in patients with degenerative dementia or chronic neuropsychiatric disease (Greenwald et al, 1989; Reifler et al., 1989; Reynolds et al., 1987) . Greenwald and colleagues (1989) studied 10 inpatients who met diagnostic criteria for depression, but were diagnosed earlier with either dementia of the Alzheimer's type or vascular dementia. The patients were treated on an inpatient ward for an average of 78 days. At the time of discharge, the depressed sample demonstrated significant improvement on the HDRS and measures of cognitive function. There was no significant change in a nondepressed control group. In contrast, Reynolds' group found no improvement on cognitive testing following treatment for depression in a small sample of cognitively impaired depressed patients. Likewise, Reifler and collegues found that depressed outpatients with Alzheimer's dementia actually declined on a brief cognitive screening test following eight weeks of pharmacological treatment for depression, despite improved depression scale ratings.
The inconsistency in these findings might be due, in part, to differences in the selection of brief dementia screening tests and clinician ratings, rather than more comprehensive neuropsychological testing. In addition, the previous studies accounted only for depression ratings, and not the full spectrum of mood states (e.g., hostility, joy) that can occur in cognitively impaired patients. In the present study, we addressed these problems while investigating the degree to which fluctuations in mood states interact with cognitive performance in a diverse sample of elderly psychiatry inpatients with varying degrees of cognitive impairment.
METHODS

Participants
Twenty-three elderly psychiatry inpatients with cognitive impairment and varying degrees of depressive symptoms or mood were studied. All were admitted to the same 18-bed geriatric psychiatry ward of a university-affiliated, urban hospital, with an average duration of 27 days. Most patients were brought to the hospital against their will with allegations of bizarre behavior and danger to self or others. Each patient was referred for neuropsychological examination as part of a standard diagnostic work-up that also included a CT head scan (MRI in some ONTOGENY OF SOCIAL MEMORY P95 cases) and serum laboratory studies to rule out metabolic encephalopathy. Based on the diagnostic work-up and review of medical records, each patient received a consensus diagnosis based on criteria published by the American Psychiatric Association (DSM-IV; American Psychiatric Association, 1994). Data on consecutive referrals was collected, but the current report is limited to those patients who evidenced at least mild cognitive impairment (see below).
All but one of the patients were women and all were Caucasian. The primary diagnoses were as follows: 8 dementia of the Alzheimer type, 3 vascular dementia, 8 schizophrenia, 2 major depressive disorder, and 2 bipolar disorder. The mean level of education for the patient sample was 10.0 years (SD = 2.4). Premorbid IQs were estimated by the method of Barona, Reynolds, and Chastain (1984) and the mean for the patient sample was 97.8 (SD = 8.2). Dementia was diagnosed in accordance with the DSM-PV standard of memory impairment plus one other cognitive deficit and significant impairment in social or occupational functioning, as determined by psychiatric interview. The presence of dementia was then confirmed with the Folstein Mini-Mental State Examination (MMSE; Folstein, Folstein, & McHugh, 1975) . The mean MMSE score for the patient sample was 22.4 (SD = 2.1). The MADRS was employed to assess each patient's level of depression. This observer-based depression rating scale includes 10 items that are scored on a 0 to 6 scale. Higher numbers reflect greater degrees of depressive symptomatology and mood.
Twelve healthy elderly volunteers between the ages of 56 ahd 82 were also examined. All had an MMSE score greater than 25. The control group included 9 women and 3 men, and 9 of the subjects were Caucasian. The mean level of education was 11.4 years (SD = 1.2) and the mean estimated premorbid IQ was 102.2 (SD = 6.8).
Exclusion criteria for both groups included a history of prolonged alcohol or substance dependence, ECT during the past three years, current medical illness likely to affect cognitive performance, and history of neurologic injury or illness unrelated to the presenting problem and likely to have affected neuropsychological function.
Treatment methods varied widely across patients, as a result of differences in diagnosis, primary symptoms, coexisting medical problems, failure to respond to treatment, and development of side effects. However, no participant received ECT. Table 1 presents medications prescribed for each patient at the time of each neuropsychological assessment. Either alone or in combination, there were seven (30%) patients treated with a seratonin reuptake inhibitor (fluoxetine, sertraline), four (17%) treated with a tricyclic antidepressant, eight (35%) treated with an anti- 
Notes: TCA = tricyclic antidepressants; SSRI = selective serotonin reuptake inhibitors; DA = dopamine agonists; BEN = benzodiazepines; AC = anticonvulsants; APS = antipsychotics; ACH = anticholinergics or antihistamines. Y indicates patient taking this form of medication at time of NP assessment. cholinergic or antihistamine medication, and eight (35%) patients were treated with an anticonvulsant or anxiolytic medication. The vast majority of the sample (n = 20 or 87%) received a neuroleptic medication at some point during hospitalization.
Measures
The neuropsychology test battery was based on a dementia research clinic examination originated at the Johns Hopkins School of Medicine (Barr, Benedict, Brandt, & Tune, 1992) and adapted for use in an inpatient setting (Benedict, Goldstein, & Derogatis, 1996; Benedict, Schretlen, Groninger, Dobraski, & Shpritz, 1996) . The examination included tests of expressive language, visuospatial processing, verbal and nonverbal memory, executive control, and emotional functioning. Visual naming was tested with the same 30-item short form of the Boston Naming Test (BNT; Kaplan, Goodglass, & Weintraub, 1983) as used previously (Barr et al., 1992; Benedict, Goldstein, et al., 1996) . The Developmental Test of Visual-Motor Integration (VMI; Beery & Buktenica, 1982) was employed to evaluate visuospatial construction. The VMI was designed to be used with children, but we have found the test useful with geriatric subjects due to its resistence to floor effects. As in previous research (Barr et al., 1992; Benedict, Goldstein, et al., 1996) , the test was scored using a method in which each of the 24 figures is scored 0 for failure or 1 for correct reproduction. Executive skills were assessed briefly with Part B of the Trail Making Test (TMT-B; Reitan, 1958) , which requires visual attention and shifting of response set.
Two recently revised learning and memory tests were also administered. The Hopkins Verbal Learning Test-Revised (HVLT-R; Benedict, Schretlen, Groninger, & Brandt, 1998) required that patients attempt to recall a list of 12 words presented over three successive learning trials. After a 20 to 25 minute delay interval, the patients were again asked to recall the same list, without the benefit of another exposure, and then asked to identify target words from memory with a "yes" response and nontargets with a "no" response. The Brief Visuospatial Memory Test-Revised (BVMT-R; Benedict, 1997 ) has a similar administration format. Patients were presented with a matrix of 6 geometric designs for 10 seconds and then asked to reproduce the designs with paper and pencil. Each design was scored 0,1, or 2, depending on localization and accuracy criteria. Hence, recall scores over learning trials 1 through 3 ranged from 0 to 12, as with the HVLT-R. In this study, only the learning measures were employed. For both HVLT-R and BVMT-R Total Recall the sum of recall trials 1 through 3 was recorded. Both the HVLT-R and BVMT-R have 6 alternate test forms that mitigate the effects of task-specific practice in serial testing protocols.
The two self-report tests of depressive symptoms and mood included the 15-item short form of the Geriatric Depression Scale (GDS; Parmelee & Katz, 1990; Parmelee, Lawton, & Katz, 1989) and an adapted version of the Derogatis Affects Balance Scale (DABS; Benedict, Goldstein, et al., 1996; Derogatis, 1975) . On the latter, subjects were asked to rank 40 mood adjectives (e.g., happy, irritable, loving) in terms of the frequency of occurrence on a 5-point scale ranging from 0 (not at all) to 4 (always). The frequency rankings were summed within each of the following eight general mood subscales: joy, contentment, vigor, affection, anxiety, depression, guilt, and hostility. Two summary scores for the frequency of positive and negative mood states were calculated in order to derive the Affects Balance Index (ABI). The ABI ranges from -4, which is the maximum negative valence, to +4, which is the maximum positive valence.
Procedure
The patients were consecutive referrals for neuropsychological examination from the geriatric psychiatry ward. In most cases, the examinations were performed within one week of admission to the hospital. Those patients meeting inclusion criteria were approached within 5 days of discharge from the hospital and asked to participate in a brief, voluntary, follow-up examination. Those agreeing to participate and signing informed consent were paid $5 in U.S. currency for their time. This protocol was approved by the Institutional Human Subjects Review Committee at the hospital in which the study was conducted.
The MADRS was not administered to control subjects, but no control subject presented complaints of depressive symptoms or dysphoria at the time of examination. All patients were examined in the same hospital as the geriatric psychiatry ward in which they were being treated. Control subjects were examined in the neuropsychology clinic, in a quiet room at their residence, or in a testing room designated at a local senior citizens recreation center. Regardless of the exam location, neuropsychological testing was always conducted in a room free of extraneous distraction and follow-up exams were performed in the same setting as the initial exam. The average test-retest interval was 30.6 (SD = 31.2) days for patients and 43.7 (SD = 31.6) days for controls.
Statistical Analyses
The patients were divided into depressed and nondepressed subgroups based on a cutoff MADRS score of 20, which distinguishes normal or mild depression from moderate or severe depression (Montgomery & Asberg, 1979 ). The depressed patients were then categorized according to the degree of pre-to post-treatment change on the MADRS. Those with at least a 10-point and 35% reduction in MADRS score were categorized as responders, and the remaining patients were labeled nonresponders. These two subgroups were then compared on cognitive testing. The general hypothesis was that responders would demonstrate a greater degree of improvement in cognitive function.
RESULTS
Demographic data and neuropsychological test results for the patient and control groups are presented in Table 2 . As can be seen, the groups were well-matched on age, education, and estimated IQ. Statistically reliable group differences were found on all of the cognitive measures. GDS and ABI scores discriminated the depressed and nondepressed patient groups significantly, as was expected. Depressed and nondepressed patients differed significantly on BNT, according to SNK post hoc comparisons. Although there were no other statistically reliable differences on cognitive testing between the patient subgroups, it is noteworthy that the depressed patients performed more poorly than did their nondepressed counterparts on every measure.
Six depressed patients met the aforementioned MADRS criteria for positive treatment response, and were designated responders. Their diagnoses were as follows: 1 (17%) dementia of the P97 Alzheimer type, 2 (33%) vascular dementia, 1 (17%) schizophrenia, 2 (33%) major depressive disorder. Four depressed patients did not show significant improvement and of these nonresponders, 3 (75%) were diagnosed with Alzheimer dementia and 1 (25%) was diagnosed with schizophrenia.
The severity of cognitive impairment as assessed by the MMSE at Exam 1 was nearly identical between responders and nonresponders (means 22.2 and 22.5, respectively), and the subgroups did not differ on Exam 1 MADRS scores by independent-sample t test. Paired-sample t tests revealed no significant gains in cognitive performance among the nonresponders or normal controls, even when a lower threshold for significance was employed ip < .10) to adjust for reduced statistical power in the former group. For responders, however, significant gains in cognitive performance were found for BNT (t(5) = 2.1, p < .10), VMI (t(5) = 15.6, p < .001), and HVLT-R Total Recall (t(5) = 2.6, p<. 05).
The Exam 1 and Exam 2 MMSE scores for the depressed patients and normals are presented in Figure 1 . It can be seen mat both subgroups were deficient on the MMSE at Exam 1. Whereas there were no reliable changes in MMSE among normals or nonresponding patients at Exam 2, responding patients showed significant improvement at Exam 2 (t(5) = 3.9, p < .05).
Change scores were calculated for each of the dependent measures. For the cognitive measures, change scores were calculated such that positive values reflected improved cognitive performance. For the depressive symptom and mood scales, change scores were based on the numerical calculation [Exam 2 -Exam 1]. Thus, larger values on the MADRS and GDS identified patients with either unchanging or worsening depression and negative mood states. Conversely, larger ABI values signified an increase in the frequency of positive versus negative mood states over the course of treatment Canonical correlation analysis was then performed to assess the relationship between the cognitive and affective change 
Notes:
One-way ANOVA significant at a =p < .01, or b = p < .001. * = group mean differs significantly from controls by Student-NewmanKeuls test using a threshold for significance of p < .05. ** = group mean differs from controls and other patient group by StudentNewman-Keuls test using a threshold for significance of p < .05. scores in the entire patient sample. In the first analysis, all change scores were entered, including the MADRS. Among the depression/mood scales, MADRS and GDS change scores were assigned substantially higher standardized canonical coefficients (.87 and .59) than ABI (.07). The cognitive test coefficients were more uniform, making it difficult to identify specific cognitive measures that could be used to reduce the variable/subject ratio in a second analysis. The second analysis was then performed retaining MADRS and GDS in the first set, and all cognitive test scores in the second. The result was a high canonical correlation r of .74 which should be interpreted conservatively given the small sample size, and the marginal test for statistical significance (p = .039).
When MADRS and GDS change scores were regressed on the cognitive change scores, in separate analyses for each cognitive measure, significant findings emerged for VMI and HVLT-R Total Recall. In each case, MADRS scores accounted for the most variance (VMI r = -.47, p < .01; HVLT-R Total Recall r = -.46, p<. 01).
DISCUSSION
The data obtained here demonstrate a significant association between changes in mood state and cognitive function among geriatric patients during acute psychiatric hospitalization. All patients were cognitively impaired on admission to the psychiatric ward and ten patients also presented with moderate or severe depression, as measured by the MADRS. Depression improved in six patients during hospitalization, and repeating the neuropsychological examination provided a means of assessing the association between reduction in depressive symptoms/mood and changes in cognitive performance. As a group, the responders showed significant gains on three tests emphasizing naming, spatial processing and memory. In contrast, there were no significant changes among either normal controls or nonresponding patients, thereby raring out the influence of practice effects. The effect size was modest for the naming task (BNT d = .5), but large for tests of spatial performance (VMI d = 1.0) and memory (HVLT-R Total Recall d = .9). 
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These preliminary findings are important because defective neuropsychological test scores could be misinterpreted as evidence for the presence of "organic" deficits and degenerative dementia. Depressive symptoms, psychological distress, and vacillations in mood state are commonly found in patients with progressive dementing disease (Alexopoulos & Abrams, 1991; Burns, 1991; Starkstein & Robinson, 1989) . To date, efforts to identify a unique symptom or neuropsychological profile for demented patients with superimposed depression have been unsuccessful (Greenwald et al., 1989; Lipsey, Spencer, Rabins, & Robinson, 1986) . Therefore, repetition of brief, neuropsychological testing procedures during psychiatric treatment remains the best way to detect a reversible-dementia syndrome in this population. Such an approach enabled us to find significant changes in multiple domains of cognitive function in our sample, which would not be possible with a single, general dementia rating scale. One caveat to the serial testing approach is the risk of inflated scores at Exam 2 due to task-specific practice, and where possible, tests with multiple test forms should be employed.
Recovery in neuropsychological test scores among depressed patients with previously diagnosed progressive dementia or chronic neuropsychiatric disease was investigated in only a few previous studies yielding conflicting results. Reifler and collegues (1989) reported decline on a cognitive screening test after eight weeks of pharmacological treatment for depression, and Reynolds and collegues (1987) reported no significant change on the MMSE in eight patients following antidepressant therapy. Greenwald and colleagues' (1989) better controlled study included a mixed sample of Alzheimer's disease and multi-infarct dementia inpatients with depression. These patients improved significantly on the HDRS during a 78-day hospitalization, and in addition, improved significantly on the MMSE. Like Corwin and collegues (1990) , we compared responding and nonresponding patients and our findings support the conclusions of Greenwald and colleagues in that significant, albeit modest, change is likely in cognitively impaired, depressed patients responding to psychiatric treatment. It is important to note, however, that despite this significant change, our patients continued to exhibit at least mild cognitive impairment after treatment.
As is apparent in Table 1 , medication regimens were quite variable in this sample and many of the medications (e.g., anticholinergic medications) employed have either direct or indirect effects on memory function. Therefore, although our study addressed the relationship between changes in mood and cognition, our research design does not isolate a causative factor in reversible dementia. Another major limitation of this study concerns differences in the diagnostic composition of the depressed and nondepressed patient groups, as well as the responder and nonresponder subgroups. Our aim was to examine consecutive referrals from a geriatric psychiatry ward, and as a result, the patient sample was quite heterogenous. Our data suggest that poor cognitive test scores can be misleading in geriatric psychiatry inpatients, as test scores may improve following even short-term treatment. Yet, it is likely that this finding varies by diagnosis. Positive response to treatment was rare among Alzheimer dementia and schizophrenia patients (one responder in each group), the two largest diagnostic subgroups in our study. In contrast, both patients diagnosed only with major depression responded favorably to treatment. Ideally, in future studies, large homogenous samples of patients with different diagnoses would be compared to determine if the pseudodementia effect found in this study can be replicated, and if it varies across etiology. We hope that these preliminary findings will serve as a basis for examining this question in a larger series of patients.
